publication date: Sep. 18, 2015
A New Doubling: Advocates, NCI Seek 7% Boost for Medical Research Funding
NIH, NCI and FDA should receive budget increases of at least 7 percent a year, the 2015 Cancer Progress Report by the American Association for Cancer Research recommends.
The NCI Bypass Budget for 2017, published almost simultaneously with the AACR report, requests a series of annual 7-percent increases for NCI, which over a decade would double the institute’s budget.
NCI Bypass Budget Calls for 7% More in 2017—and Doubling by 2026
The NCI Bypass Budget for 2017 asks for a 7-percent increase over fiscal 2016, followed by a series of annual 7-percent increases that would continue through 2026, when the institute’s budget would double.
The Bypass Budget is submitted by the NCI director to the U.S. President under a unique authority given to NCI under the National Cancer Act of 1971. Over the years, the budgets have had different functions, which reflected the priorities—and styles—of the institute directors who submitted them.
Lowy: Increase for Cancer Center Grants Is Contingent on FY2016 Appropriations
NCI is planning to increase funding for the Cancer Center Core Grants, Acting Director Douglas Lowy said to the National Cancer Advisory Board at a meeting Sept. 16.
“Whatever we do, I’m not going to talk about the FY16 budget, but I just want to point out that it has not been passed, and until it is passed and until we get an increase in our appropriation, we would need to hold in abeyance the commitment for full funding for the increases in order to be fiscally responsible,” said Lowy during his second director’s report since he became acting director.
Robert Califf Tapped for FDA Commissioner Position
President Barack Obama nominated Robert Califf to the post of Commissioner of Food and Drugs.
Earlier this year, Califf was named FDA Deputy Commissioner for Medical Products and Tobacco, a de facto No. 2 post at the agency. Califf, 63, is an expert in cardiology, clinical research, and medical economics.
NCI Funds Five Teams to Work with Animal Models for Children’s Cancer
NCI has funded five research teams to participate in its Pediatric Preclinical Testing Consortium.
The consortium is designed to focus on preclinical models in order to help prioritize agents for entry into clinical trials.
Jones, Parwani recruited to key roles in Ohio State Wexner pathology programs
Broad Institute, MD Anderson Cancer Center designated as Genome Characterization Centers
Robin Davisson named president and CEO-elect of Melanoma Research Alliance
MD Anderson and Esperance Pharmaceuticals enter strategic alliance
|Drugs and Targets|
AbbVie submits sNDA for Imbruvica in CLL Patients
- FDA grants fast track designation to Can-Fite BioPharma Ltd.’s liver cancer drug
FDA accepts Wellstat Therapeutics’ NDA for treatment of chemotherapy overdose
- FDA and the European Medicines Agency accepts regulatory applications for Gilotrif
AstraZeneca and Peregrine Pharmaceuticals enter into immunotherapy clinical trial collaboration
- ICON teams up with IBM to reduce time and costs of drug development